GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News:
Today Vitrolife (STO:VITR) is publishing the Annual Report for 2011 in Swedish. The Annual Report is attached to this press release and will also be available on www.vitrolife.com.
http://feed.ne.cision.com/client/waymaker1/WOLReleaseFile.aspx?id=2122695&fn=wkr0001.pdf
The printed version of the Annual Report will be distributed by mail during the week commencing 2 April. It will be distributed to Nordic shareholders who are new from last year and to remaining shareholders who have requested that the annual report should be sent to them.
The printed version of the Annual Report can be ordered on the company's website www.vitrolife.com, by phone +46 (0)31 721 80 00 or by email info@vitrolife.com.
VITROLIFE AB (publ)
Vitrolife (http://www.vitrolife.com/en/Corporate/) is a global biotechnology/medical device Group that works in the areas of Fertility and Transplantation. The Fertility (http://www.vitrolife.com/en/Fertility/) product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. The Transplantation (http://www.xvivoperfusion.com/transplantation/) product area works with solutions and systems for assessing and preserving organs outside the body, so as to be able to select usable organs and keep them in optimal condition pending transplantation.
Vitrolife (http://www.vitrolife.com/en/Corporate/) today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is listed on NASDAQ OMX Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE13469), Small Cap.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on March 26, 2012 at 11:00 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://www.cisionwire.com